1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Ivermectin / Abamectin Liquid Formulation

Manufacturer or supplier's details
Company: MSD
Address: 50 Tuas West Drive
Singapore - Singapore 638408
Telephone: 908-740-4000
Emergency telephone number: 65 6697 2111 (24/7/365)
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

2. HAZARDS IDENTIFICATION

GHS Classification
Acute toxicity (Oral): Category 4
Acute toxicity (Inhalation): Category 4
Skin corrosion/irritation: Category 2
Serious eye damage/eye irritation: Category 2
Reproductive toxicity: Category 1B
Specific target organ toxicity - single exposure (Oral): Category 2 (Central nervous system)
Specific target organ toxicity - single exposure: Category 3
Specific target organ toxicity - repeated exposure: Category 2 (Central nervous system)
Short-term (acute) aquatic hazard: Category 1
Long-term (chronic) aquatic hazard: Category 1
SAFETY DATA SHEET

Ivermectin / Abamectin Liquid Formulation

Signal word

Hazard pictograms

Hazard statements

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapours.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.
P302 + P352 IF ON SKIN: Wash with plenty of water.
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.
P391 Collect spillage.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.
SAFETY DATA SHEET

Ivermectin / Abamectin Liquid Formulation

Version 5.0  Revision Date: 23.03.2020  SDS Number: 1210016-00010  Date of last issue: 13.09.2019

Other hazards which do not result in classification
None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-Methyl-2-pyrrolidone</td>
<td>872-50-4</td>
<td>&gt;= 20 - &lt; 30</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>&gt;= 1 - &lt; 2.5</td>
</tr>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
<td>71751-41-2</td>
<td>&gt;= 1 - &lt; 2.5</td>
</tr>
<tr>
<td>(dl)-a-Tocopheryl acetate</td>
<td>7695-91-2</td>
<td>&lt; 0.1</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed : Harmful if swallowed or if inhaled. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation. May damage the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES
### 6. ACCIDENTAL RELEASE MEASURES

| Personal precautions, protective equipment and emergency procedures | Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations. |
| Environmental precautions | Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |

### 7. HANDLING AND STORAGE

| Technical measures | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | Do not get on skin or clothing. |
Do not breathe vapours or spray mist. 
Do not swallow. 
Do not get in eyes. 
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. 
Keep container tightly closed. 
Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitisers. 
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: 
Keep in properly labelled containers. 
Store locked up. 
Keep tightly closed. 
Keep in a cool, well-ventilated place. 
Store in accordance with the particular national regulations.

Materials to avoid: 
Do not store with the following product types: 
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>TWA</td>
<td>0.05 mg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wipe limit 0.5 mg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
<td>71751-41-2</td>
<td>TWA</td>
<td>30 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wipe limit 300 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>(dl)-a-Tocopheryl acetate</td>
<td>7695-91-2</td>
<td>TWA</td>
<td>5000 ug/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Biological occupational exposure limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Control parameters</th>
<th>Biological specimen</th>
<th>Sampling time</th>
<th>Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-Methyl-2-pyrrolidone</td>
<td>872-50-4</td>
<td>5-Hydroxy-N-methyl-2-pyrrolidone</td>
<td>Urine</td>
<td>End of shift (As soon as possible after exposure ceases)</td>
<td>100 mg/l</td>
<td>ACGIH BEI</td>
</tr>
</tbody>
</table>

Engineering measures: 
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections). 
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to
protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

**Personal protective equipment**

- **Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  - **Filter type**: Combined particulates and organic vapour type
- **Hand protection**: Chemical-resistant gloves
- **Eye protection**: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- **Skin and body protection**: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
- **Hygiene measures**: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

- **Appearance**: liquid
- **Colour**: light yellow
- **Odour**: characteristic
- **Odour Threshold**: No data available
- **pH**: Not applicable
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling**: No data available
10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents.
11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Harmful if swallowed or if inhaled.

**Product:**

- **Acute oral toxicity**: Acute toxicity estimate: 1,031 mg/kg
  - Method: Calculation method
- **Acute inhalation toxicity**: Acute toxicity estimate: 1.84 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist
  - Method: Calculation method
- **Acute dermal toxicity**: Acute toxicity estimate: > 2,000 mg/kg
  - Method: Calculation method

**Components:**

**N-Methyl-2-pyrrolidone:**

- **Acute oral toxicity**: LD50 (Rat): 4,150 mg/kg
- **Acute inhalation toxicity**: LC50 (Rat): > 5.1 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist
  - Method: OECD Test Guideline 403
- **Acute dermal toxicity**: LD50 (Rat): > 5,000 mg/kg

**Ivermectin:**

- **Acute oral toxicity**: LD50 (Rat): 50 mg/kg
  - LD50 (Mouse): 25 mg/kg
  - LD50 (Monkey): > 24 mg/kg
  - Target Organs: Central nervous system
  - Symptoms: Vomiting, Dilatation of the pupil
  - Remarks: No mortality observed at this dose.
- **Acute inhalation toxicity**: LC50 (Rat): 5.11 mg/l
  - Exposure time: 1 h
  - Test atmosphere: dust/mist
- **Acute dermal toxicity**: LD50 (Rabbit): 406 mg/kg
  - LD50 (Rat): > 660 mg/kg
Abamectin (combination of avermectin B1a and avermectin B1b):

- **Acute oral toxicity**: LD50 (Rat): 24 mg/kg
  - LD50 (Mouse): 10 mg/kg
  - LDLo (Monkey): 24 mg/kg
  - Symptoms: Dilatation of the pupil

- **Acute inhalation toxicity**: LC50 (Rat): 0.023 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist

- **Acute dermal toxicity**: LD50 (Rat): 330 mg/kg
  - LD50 (Rabbit): 2,000 mg/kg

*(dl)-a-Tocopheryl acetate:

- **Acute oral toxicity**: LD50 (Rat): > 5,000 mg/kg
- **Acute dermal toxicity**: LD50 (Rat): > 3,000 mg/kg

  Assessment: The substance or mixture has no acute dermal toxicity

**Skin corrosion/irritation**

- Causes skin irritation.

**Components:**

- **N-Methyl-2-pyrrolidone:**
  - **Result**: Skin irritation

- **Ivermectin:**
  - **Species**: Rabbit
  - **Result**: No skin irritation

- **Abamectin (combination of avermectin B1a and avermectin B1b):**
  - **Species**: Rabbit
  - **Result**: No skin irritation

- **(dl)-a-Tocopheryl acetate:**
  - **Species**: Rabbit
  - **Method**: OECD Test Guideline 404
  - **Result**: No skin irritation

**Serious eye damage/eye irritation**

- Causes serious eye irritation.
Components:

N-Methyl-2-pyrrolidone:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Irritation to eyes, reversing within 21 days</td>
</tr>
</tbody>
</table>

Ivermectin:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Mild eye irritation</td>
</tr>
</tbody>
</table>

Abamectin (combination of avermectin B1a and avermectin B1b):

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Mild eye irritation</td>
</tr>
</tbody>
</table>

(dl)-a-Tocopheryl acetate:

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>No eye irritation</td>
</tr>
<tr>
<td>Method</td>
<td>OECD Test Guideline 405</td>
</tr>
</tbody>
</table>

Respiratory or skin sensitisation

Skin sensitisation
- Not classified based on available information.

Respiratory sensitisation
- Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Local lymph node assay (LLNA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure routes</td>
<td>Skin contact</td>
</tr>
<tr>
<td>Species</td>
<td>Mouse</td>
</tr>
<tr>
<td>Method</td>
<td>OECD Test Guideline 429</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

Ivermectin:

<table>
<thead>
<tr>
<th>Exposure routes</th>
<th>Dermal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Humans</td>
</tr>
<tr>
<td>Result</td>
<td>Does not cause skin sensitisation.</td>
</tr>
</tbody>
</table>

Abamectin (combination of avermectin B1a and avermectin B1b):

<table>
<thead>
<tr>
<th>Exposure routes</th>
<th>Dermal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Not a skin sensitizer.</td>
</tr>
</tbody>
</table>

(dl)-a-Tocopheryl acetate:

<table>
<thead>
<tr>
<th>Exposure routes</th>
<th>Skin contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Humans</td>
</tr>
</tbody>
</table>
Result: negative

Germ cell mutagenicity
Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:
- Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
  Method: OECD Test Guideline 471
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Method: OECD Test Guideline 476
  Result: negative
- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  Result: negative

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Mouse
  Application Route: Ingestion
  Method: OECD Test Guideline 474
  Result: negative
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
  Species: Hamster
  Application Route: Ingestion
  Method: OECD Test Guideline 475
  Result: negative

Ivermectin:
- Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  Test system: human diploid fibroblasts
  Result: negative
- Test Type: Mouse Lymphoma
  Result: negative

Abamectin (combination of avermectin B1a and avermectin B1b):
- Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Test system: Chinese hamster lung cells
  Result: negative
Test Type: Alkaline elution assay  
Result: negative

Genotoxicity in vivo  :  Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

(dl)-a-Tocopheryl acetate:  
Genotoxicity in vitro  :  Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Genotoxicity in vivo  :  Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

N-Methyl-2-pyrrolidone:
Species  :  Rat  
Application Route  :  Ingestion  
Exposure time  :  2 Years  
Result  :  negative

Species  :  Rat  
Application Route  :  Inhalation (vapour)  
Exposure time  :  2 Years  
Result  :  negative

Ivermectin:
Species  :  Rat  
Application Route  :  Oral  
NOAEL  :  1.5 mg/kg body weight  
Result  :  negative  
Remarks  :  Based on data from similar materials

Species  :  Mouse  
Application Route  :  Oral  
NOAEL  :  2.0 mg/kg body weight  
Result  :  negative  
Remarks  :  Based on data from similar materials
Abamectin (combination of avermectin B1a and avermectin B1b):

- **Species**: Rat
- **Application Route**: Oral
- **Exposure time**: 105 weeks
- **Result**: negative

- **Species**: Mouse
- **Application Route**: Oral
- **Exposure time**: 93 weeks
- **Result**: negative

(dl)-a-Tocopheryl acetate:

- **Species**: Rat
- **Application Route**: Ingestion
- **Exposure time**: 104 weeks
- **Result**: negative

Reproductive toxicity

May damage the unborn child.

**Components:**

**N-Methyl-2-pyrrolidone:**

- **Effects on fertility**: Test Type: Two-generation reproduction toxicity study
  - Species: Rat
  - Application Route: Ingestion
  - Method: OECD Test Guideline 416
  - Result: negative

- **Effects on foetal development**: Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Ingestion
  - Method: OECD Test Guideline 414
  - Result: negative

  Test Type: Fertility/early embryonic development
  - Species: Rat
  - Application Route: inhalation (vapour)
  - Result: positive

  Test Type: Embryo-foetal development
  - Species: Rabbit
  - Application Route: Ingestion
  - Result: positive

**Reproductive toxicity - Assessment**: Clear evidence of adverse effects on development, based on animal experiments.

**Ivermectin:**

- **Effects on fertility**: Test Type: Fertility
  - Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development:
- Test Type: Development
  - Species: Mouse
  - Application Route: Oral
  - Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
  - Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

- Test Type: Development
  - Species: Rat
  - Application Route: Oral
  - Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
  - Result: Embryotoxic effects and adverse effects on the offspring were detected.
  - Remarks: The mechanism or mode of action may not be relevant in humans.

- Test Type: Development
  - Species: Rabbit
  - Application Route: Oral
  - Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

**Abamectin (combination of avermectin B1a and avermectin B1b):**

**Effects on fertility:**
- Test Type: Fertility
  - Species: Rat, male
  - Application Route: Oral
  - Result: Effects on fertility

- Test Type: Two-generation reproduction toxicity study
  - Species: Rat
  - Application Route: Oral
  - Early Embryonic Development: NOAEL: 0.12 mg/kg body weight
  - Result: Fetotoxicity

**Effects on foetal development:**
- Test Type: Embryo-foetal development
  - Species: Mouse
  - Application Route: Oral
  - General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight
  - Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
  - Result: Cleft palate
  - Remarks: Adverse developmental effects were observed

- Test Type: Embryo-foetal development
  - Species: Rabbit
  - Application Route: Oral
  - Developmental Toxicity: LOAEL: 2 mg/kg body weight
  - Result: Cleft palate, Teratogenic effects, Reduced embryonic
survival
Remarks: Adverse developmental effects were observed

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
Result: Teratogenic effects

Reproductive toxicity - Assessment: Some evidence of adverse effects on sexual function and fertility, based on animal experiments. Some evidence of adverse effects on development, based on animal experiments.

(dl)-a-Tocopheryl acetate:
Effects on fertility: Test Type: Reproduction/Developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Result: negative

STOT - single exposure
May cause respiratory irritation.
May cause damage to organs (Central nervous system) if swallowed.

Components:

N-Methyl-2-pyrrolidone:
Assessment: May cause respiratory irritation.

Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs.

STOT - repeated exposure
May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:

Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Abamectin (combination of avermectin B1a and avermectin B1b):
Exposure routes: Ingestion
Target Organs: Central nervous system
**Assessment**
Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**N-Methyl-2-pyrrolidone:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat, male</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>169 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>433 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
<tr>
<td>Method</td>
<td>OECD Test Guideline 408</td>
</tr>
</tbody>
</table>

**Species**

<table>
<thead>
<tr>
<th>Rat</th>
<th>0.5 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>1 mg/l</td>
</tr>
<tr>
<td>Application Route</td>
<td>inhalation (dust/mist/fume)</td>
</tr>
<tr>
<td>Exposure time</td>
<td>96 Days</td>
</tr>
<tr>
<td>Method</td>
<td>OECD Test Guideline 413</td>
</tr>
</tbody>
</table>

**Species**

<table>
<thead>
<tr>
<th>Rabbit</th>
<th>826 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>1,653 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Skin contact</td>
</tr>
<tr>
<td>Exposure time</td>
<td>20 Days</td>
</tr>
<tr>
<td>Method</td>
<td></td>
</tr>
</tbody>
</table>

**Ivermectin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>0.5 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>1 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>14 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Dilatation of the pupil, Tremors, Lack of coordination, anorexia</td>
</tr>
</tbody>
</table>

**Species**

<table>
<thead>
<tr>
<th>Monkey</th>
<th>1.2 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>2 Weeks</td>
</tr>
<tr>
<td>Remarks</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

**Species**

<table>
<thead>
<tr>
<th>Rat</th>
<th>0.4 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>0.8 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>Exposure time</td>
<td>3 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>spleen, Bone marrow, Kidney</td>
</tr>
</tbody>
</table>

**Abamectin (combination of avermectin B1a and avermectin B1b):**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>1.5 mg/kg</td>
</tr>
</tbody>
</table>
### Application Route
- Oral

### Exposure time
- 24 Months

### Target Organs
- Central nervous system

### Symptoms
- Tremors, ataxia

### Species
- Mouse

### NOAEL
- 4.0 mg/kg

### Application Route
- Oral

### Exposure time
- 24 Months

### Target Organs
- Central nervous system

### Symptoms
- Tremors, ataxia

### Remarks
- Mortality observed

### Species
- Dog

### NOAEL
- 0.25 mg/kg

### LOAEL
- 0.5 mg/kg

### Application Route
- Oral

### Exposure time
- 53 Weeks

### Target Organs
- Central nervous system

### Symptoms
- Tremors, weight loss

### Species
- Monkey

### NOAEL
- 1.0 mg/kg

### Application Route
- Oral

### Exposure time
- 14 Weeks

### Target Organs
- Central nervous system

### (dl)-a-Tocopheryl acetate:

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>500 mg/kg</td>
<td>Ingestion</td>
<td>90 Days</td>
</tr>
</tbody>
</table>

### Aspiration toxicity
Not classified based on available information.

### Experience with human exposure

### Components:

#### N-Methyl-2-pyrrolidone:

**Skin contact**
- Symptoms: Skin irritation

**Ivermectin**

**Skin contact**
- Remarks: Can be absorbed through skin.

**Eye contact**
- Remarks: May irritate eyes.

**Ingestion**
- Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

#### Abamectin (combination of avermectin B1a and avermectin B1b):

**Ingestion**
- Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing
12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

**N-Methyl-2-pyrrolidone:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 1,000 mg/l
Exposure time: 24 h
Method: DIN 38412

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l
Exposure time: 72 h
EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l
Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 12.5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 600 mg/l
Exposure time: 30 min
Method: ISO 8192

**Ivermectin:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l
Exposure time: 96 h
LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 10,000

M-Factor (Chronic aquatic toxicity) : 10,000

**Abamectin (combination of avermectin B1a and avermectin B1b):**
<table>
<thead>
<tr>
<th>Test Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Toxicity to fish</strong></td>
<td></td>
</tr>
<tr>
<td><strong>LC50 (Oncorhynchus mykiss (rainbow trout))</strong></td>
<td>3.2 µg/l Exposure time: 96 h</td>
</tr>
<tr>
<td><strong>LC50 (Lepomis macrochirus (Bluegill sunfish))</strong></td>
<td>9.6 µg/l Exposure time: 96 h</td>
</tr>
<tr>
<td><strong>LC50 (Ictalurus punctatus (channel catfish))</strong></td>
<td>24 µg/l Exposure time: 96 h</td>
</tr>
<tr>
<td><strong>LC50 (Cyprinus carpio (Carp))</strong></td>
<td>42 µg/l Exposure time: 96 h</td>
</tr>
<tr>
<td><strong>LC50 (Cyprinodon variegatus (sheepshead minnow))</strong></td>
<td>15 µg/l Exposure time: 96 h</td>
</tr>
<tr>
<td><strong>Toxicity to daphnia and other aquatic invertebrates</strong></td>
<td>LC50 (Americamysis): 0.022 µg/l Exposure time: 96 h</td>
</tr>
<tr>
<td><strong>EC50 (Daphnia magna (Water flea))</strong></td>
<td>0.34 µg/l Exposure time: 48 h</td>
</tr>
<tr>
<td><strong>Toxicity to algae/aquatic plants</strong></td>
<td>EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h</td>
</tr>
<tr>
<td><strong>M-Factor (Acute aquatic toxicity)</strong></td>
<td>10,000</td>
</tr>
<tr>
<td><strong>Toxicity to fish (Chronic toxicity)</strong></td>
<td>NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l Exposure time: 32 d</td>
</tr>
<tr>
<td><strong>Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)</strong></td>
<td>NOEC (Daphnia magna (Water flea)): 0.03 µg/l Exposure time: 21 d</td>
</tr>
<tr>
<td><strong>M-Factor (Chronic aquatic toxicity)</strong></td>
<td>10,000</td>
</tr>
<tr>
<td><strong>Toxicity to microorganisms</strong></td>
<td>EC50: &gt; 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition</td>
</tr>
<tr>
<td><strong>(dl)-a-Tocopheryl acetate:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Toxicity to fish</strong></td>
<td>LC50 (Oncorhynchus mykiss (rainbow trout)): &gt; 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203</td>
</tr>
<tr>
<td><strong>Toxicity to daphnia and other aquatic invertebrates</strong></td>
<td>EC50 (Daphnia magna (Water flea)): &gt; 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202</td>
</tr>
<tr>
<td><strong>Toxicity to algae/aquatic plants</strong></td>
<td>ErC50 (Pseudokirchneriella subcapitata (green algae)): &gt; 100 mg/l Exposure time: 72 h</td>
</tr>
</tbody>
</table>
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): \(\geq\) 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity): NOEC (Oncorhynchus mykiss (rainbow trout)): 100 mg/l
Exposure time: 28 d

Toxicity to microorganisms: EC50: > 927 mg/l
Exposure time: 30 min
Method: ISO 8192

Persistence and degradability

Components:

N-Methyl-2-pyrrolidone:

Biodegradability: Result: Readily biodegradable.
Biodegradation: 73 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Ivermectin:

Biodegradability: Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 240 d

Abamectin (combination of avermectin B1a and avermectin B1b):

Stability in water: Hydrolysis: 50 % (< 12 h)

(dl)-a-Tocopheryl acetate:

Biodegradability: Result: Not readily biodegradable.
Biodegradation: 21.7 - 31 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Bioaccumulative potential

Components:

N-Methyl-2-pyrrolidone:

Partition coefficient: n-octanol/water: log Pow: -0.46
Method: OECD Test Guideline 107

Ivermectin:

Bioaccumulation: Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water: log Pow: 3.22
Abamectin (combination of avermectin B1a and avermectin B1b):

- **Bioaccumulation**: Bioconcentration factor (BCF): 52
- **Partition coefficient: n-octanol/water**: log Pow: 4
- **Mobility in soil**

**Components:**

Abamectin (combination of avermectin B1a and avermectin B1b):

- Distribution among environmental compartments: log Koc: > 3.6

**Other adverse effects**

No data available

### 13. DISPOSAL CONSIDERATIONS

**Disposal methods**
- **Waste from residues**: Dispose of in accordance with local regulations.
- **Contaminated packaging**: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

### 14. TRANSPORT INFORMATION

**International Regulations**

**UNRTDG**
- **UN number**: UN 3082
- **Proper shipping name**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b), Ivermectin)
- **Class**: 9
- **Packing group**: III
- **Labels**: 9

**IATA-DGR**
- **UN/ID No.**: UN 3082
- **Proper shipping name**: Environmentally hazardous substance, liquid, n.o.s. (Abamectin (combination of avermectin B1a and avermectin B1b), Ivermectin)
- **Class**: 9
- **Packing group**: III
- **Labels**: Miscellaneous
- **Packing instruction (cargo aircraft)**: 964
- **Packing instruction (passenger aircraft)**: 964
- **Environmentally hazardous**: yes

**IMDG-Code**
- **UN number**: UN 3082
- **Proper shipping name**: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
SAFETY DATA SHEET

Ivermectin / Abamectin Liquid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.0</td>
<td>23.03.2020</td>
<td>1210016-00010</td>
<td>13.09.2019</td>
<td>10.01.2017</td>
</tr>
</tbody>
</table>

N.O.S.  
(Abamectin (combination of avermectin B1a and avermectin B1b), Ivermectin)

<table>
<thead>
<tr>
<th>Class</th>
<th>: 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Packing group</td>
<td>: III</td>
</tr>
<tr>
<td>Labels</td>
<td>: 9</td>
</tr>
<tr>
<td>EmS Code</td>
<td>: F-A, S-F</td>
</tr>
<tr>
<td>Marine pollutant</td>
<td>: yes</td>
</tr>
</tbody>
</table>

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 15. REGULATORY INFORMATION

**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and Environmental Protection and Management (Hazardous Substances) Regulations: Not applicable

Fire Safety (Petroleum and Flammable Materials) Regulations: Not applicable

The components of this product are reported in the following inventories:

<table>
<thead>
<tr>
<th>AICS</th>
<th>: not determined</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSL</td>
<td>: not determined</td>
</tr>
<tr>
<td>IECSC</td>
<td>: not determined</td>
</tr>
</tbody>
</table>

### 16. OTHER INFORMATION

**Further information**


Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format: dd.mm.yyyy
## SAFETY DATA SHEET

### Ivermectin / Abamectin Liquid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.0</td>
<td>23.03.2020</td>
<td>1210016-00010</td>
<td>13.09.2019</td>
<td>10.01.2017</td>
</tr>
</tbody>
</table>

### Full text of other abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACGIH BEI</td>
<td>ACGIH - Biological Exposure Indices (BEI)</td>
</tr>
</tbody>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

SG / EN